Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials

Table 2

Adverse effects associated with gefitinib.

Adverse effect	No. of studies	Model	RR (95%CI)	P value	Heterogeneity (p,I^2)	Conclusion
Diarrhea	6	Fixed	4.29(1.96, 9.41)	0.0003	P=0.62; I^2=0%	Positive
Mucositis	6	Fixed	1.20 (0.96, 1.50)	0.10	P=0.86, I^2=0%	Negative
Skin toxicity	6	Fixed	1.71 (1.06, 2.74)	0.03	P=0.24; I^2=26%	Positive
Dysphagia	4	Fixed	0.90 (0.57, 1.42)	0.65	P=0.17; I^2=40%	Negative
Nausea	4	Fixed	0.98 (0.47, 2.02)	0.95	P=0.55; I^2=0%	Negative
Vomiting	4	Fixed	1.01 (0.49, 2.10)	0.97	P=0.60; I^2=0%	Negative
Weight loss	3	Fixed	0.48 (0.12, 1.92)	0.30	P=0.73; I^2=0%	Negative
Fibrosis	2	Fixed	0.77 (0.43, 1.40)	0.40	P=1.00; I^2=0%	Negative
Neutropenia	2	Fixed	0.97 (0.46, 2.07)	0.94	P=0.92; I^2=0%	Negative
Leukopenia	2	Fixed	1.20 (0.60, 2.39)	0.60	P=0.88; I^2=0%	Negative
Oedema	2	Fixed	1.00 (0.55, 1.82)	0.99	P=0.96; I^2=0%	Negative
Xerostomia	2	Fixed	0.94 (0.41, 2.16)	0.88	P=0.60; I^2=0%	Negative
Fatigue	3	Fixed	0.97 (0.54, 1.72)	0.91	P=0.27; I^2=24%	Negative
Anemic	2	Random	1.00 (0.04, 22.86)	1.00	P=0.08; I^2=67%	Negative
Hemorrhage	2	Random	1.30 (0.07, 24.23)	0.86	P=0.11; I^2=61%	Negative